84.81
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $84.81, with a volume of 919.10K.
It is up +0.00% in the last 24 hours and down -5.51% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$84.88
Open:
$84.82
24h Volume:
919.10K
Relative Volume:
0.55
Market Cap:
$44.00B
Revenue:
$9.93B
Net Income/Loss:
$1.12B
P/E Ratio:
37.70
EPS:
2.25
Net Cash Flow:
$1.58B
1W Performance:
-4.18%
1M Performance:
-5.51%
6M Performance:
+0.17%
1Y Performance:
-4.98%
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALC
Alcon Inc
|
84.86 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
ISRG
Intuitive Surgical Inc
|
510.29 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
169.00 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
RMD
Resmed Inc
|
250.80 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
WST
West Pharmaceutical Services Inc
|
218.57 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
May-14-25 | Reiterated | BTIG Research | Buy |
Mar-28-25 | Reiterated | Needham | Buy |
Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
Jan-24-25 | Reiterated | Needham | Buy |
Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
Dec-17-24 | Reiterated | Needham | Buy |
Nov-12-24 | Reiterated | Needham | Buy |
Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
Apr-10-24 | Initiated | Goldman | Buy |
Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
Jan-23-24 | Initiated | Bernstein | Outperform |
Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
Dec-12-23 | Initiated | Stifel | Buy |
Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
Dec-22-22 | Initiated | Mizuho | Buy |
Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
May-13-22 | Resumed | Credit Suisse | Outperform |
May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
Apr-08-22 | Initiated | Needham | Buy |
Mar-11-22 | Initiated | BofA Securities | Buy |
Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-01-21 | Initiated | Oppenheimer | Perform |
Jul-14-21 | Initiated | Deutsche Bank | Buy |
May-06-21 | Upgrade | Citigroup | Sell → Neutral |
Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mar-26-20 | Upgrade | Argus | Hold → Buy |
Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
Mar-13-20 | Upgrade | UBS | Neutral → Buy |
Mar-05-20 | Initiated | Citigroup | Neutral |
Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
Jan-08-20 | Initiated | Argus | Hold |
Oct-29-19 | Initiated | Stephens | Equal-Weight |
Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
Jun-14-19 | Initiated | BTIG Research | Neutral |
May-10-19 | Initiated | Robert W. Baird | Outperform |
May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
Alcon Gets First FDA Approval Since Novartis Spinoff - Orange County Business Journal
Alcon’s Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' (NYSE:ALC) - Seeking Alpha
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
Phacoemulsification Devices Market Is Booming Worldwide - openPR.com
Alcon: Achieving UDI Compliance with Veeva RIM - Veeva
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stoc - GuruFocus
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stock News - GuruFocus
Citi more constructive on EU MedTech: Upgrades Demant; Alcon top pick - Investing.com Canada
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN
BofA Securities lowers Alcon stock price target after Q1 results By Investing.com - Investing.com South Africa
BofA Securities lowers Alcon stock price target after Q1 results - Investing.com Australia
Refractive Surgery Market Is Booming So Rapidly 2025-2032 - openPR.com
Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN
Citi maintains Buy on Alcon, price target CHF99 after FDA nod - Investing.com Nigeria
Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch By Investing.com - Investing.com Canada
Citi maintains Buy on Alcon, price target CHF99 after FDA nod By Investing.com - Investing.com South Africa
FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN
US FDA approves Alcon's new dry-eye drug - Reuters
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times
Alcon receives FDA approval for Tryptyr to treat dry eye disease - World Pharmaceutical Frontiers
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target - TipRanks
US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com
US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO
Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus
US FDA approves Alcon's new dry-eye drug (May 28) - marketscreener.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus
Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease | ALC Stock News - GuruFocus
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.
BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa
DOJ Requires Keysight to Shed Spirent Units Before $1.57 Billion Acquisition Proceeds - PYMNTS.com
BTIG maintains Alcon stock Buy rating, $99 target - Investing.com
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):